nach oben

Erschienen in:

21.09.2016 | Research Article

Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis

verfasst von: J. Sanz, N. Rodríguez, P. Foro, J. Dengra, A. Reig, P. Pérez, I. Membrive, A. Ortiz, M. Codinach, M. Algara

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the impact of hypofractionated boost after hypofractionated whole breast irradiation in breast carcinoma.

Methods and materials

Patients after breast conservative surgery were treated all time with hypofractionation of 2.67 Gy/day. Whole breast dose was 40.05 Gy followed in case of risk of local relapse by a boost of 16.02 Gy or 8.01 Gy. Acute and chronic toxicity results were evaluated including cosmetic software-assisted assessment and objective evaluation of fibrosis parameters (elasticity and hydration) by means of a skin tester.

Results

A total of 362 patients were evaluated. Acute toxicities comprised grade 1 dermatitis in 48.1 %, grade 2 in 44.5 % and grade 3 in 17 patients 4.7 %, respectively. After a median follow-up of 4.5 years, in 308 cases (86.6 %) there was no chronic skin or subcutaneous changes. In the first consecutive 50 patients, measures with skin tester showed no statistical differences in parameters for skin and subcutaneous fibrosis. Cosmetic results were considered excellent and good in 26 and 62 %, respectively.

Conclusions

Boost to tumour bed with hypofractionated doses is well tolerated and acute and chronic toxicities are mild with good cosmetic results. Objective systems are encouraging methods to assess skin quality and cosmesis.

Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333(22):1456–61.CrossRefPubMed

Bartelink H, Horio JC, Poortmans PM, Struikmans H, van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 Trial. J Clin Oncol. 2007;25(22):3259–65.CrossRefPubMed

Guinot JL, Tortajada MI, Carrascosa M, Crispín V, Otero A, Ríos B, et al. Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma. Clin Transl Oncol. 2012;14(2):109–15.CrossRefPubMed

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Leeet PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed

Whelan T, Pignol J, Levin M, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. NEJM. 2010;362:513–20.CrossRefPubMed

Smith B, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott G, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59–68.CrossRefPubMed

American Society for Radiation Oncology. Choose Wisely. 2013. http://www.choosingwisely.org/clinician-lists/american-society-radiation-oncology-whole-breast-radiotherapy/. Accessed 7 March 2016.

Montero A, Sanz X, Herranz R, Cabrera D, Arenas M, Bayo E, et al. Accelerated hypofractionated breast radiotherapy: fAQs (frequently asked questions) and facts. Breast. 2014;23(4):299–309.CrossRefPubMed

Hoeller U, Khulmey Bajrovic A, Grader K, Berger J, Tribius S, et al. Cosmesis from the patient’s and the doctor’s view. Int J Radiat Oncol Biol Phys. 2003;57:345–54.CrossRefPubMed

10.

Harris JR, Levin MB, Svensson G, Hellmann S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Phys. 1979;5(2):257–61.CrossRef

11.

Cardoso J, Cardoso M. Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment. J Artif Intell Med. 2007;40:115–6.CrossRef

12.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–71.CrossRefPubMed

13.

Platainotis GA, Theofanopoulou MA, Sotiriadou K, Kyrgias G. Hypofractionated radiotherapy for breast cancer patients treated by breast-conserving surgery: short-term morbidity and preliminary results. Breast Cancer. 2010;17:42–7.CrossRef

14.

Deantonio L, Gambaro G, Beldi D, Masini L, Tunesi S, Magnani C, et al. Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol. 2010;5:112.CrossRefPubMedPubMedCentral

15.

Pinnarò P, Soriani A, Landoni V, Giordano C, Papale M, Marsella A, et al. Accelerated hypofractionated radiotherapy as adjuvant regiment after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years. J Exp clin n.a res. 2010;29:1–9.

16.

Ivaldi GB, Leonardi MC, Orecchia R, Zerini D, Morra A, Galimberti V, et al. Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women. Int J Radiat Oncol Biol Phys. 2008;72(2):485–93.CrossRefPubMed

17.

Karasawa K, Kunogi H, Hirai T, Hojo H, Hirowatari H, Izawa H, et al. Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients. Breast Cancer. 2014;21:402–8.CrossRefPubMed

18.

Meei Teh AY, Walsh L, Purdie TG, Mosseri A, Xu W, Levin W, et al. Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy-A feasibility and toxicity study. Radiother Oncol. 2012;102:89–95.CrossRef

19.

Yarnold J, Ashton A, Blis J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long terms of a randomized trial. Radiat Oncol. 2005;75:9–17.CrossRef

20.

Qi XS, White J, Li XA. Is α/β for breast cancer really low? Radiother Oncol. 2011;100(2):282–8.CrossRefPubMed

21.

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefPubMed

22.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.CrossRefPubMed

23.

Acute and late radiation effects were evaluated and graded according to Common Terminology Criteria for Adverse Events (http://evs.nci.nih.gov/ftp1/CTCAE). Acute and late radiation effects were evaluated and graded according to Common Terminology Criteria for Adverse Events (http://evs.nci.nih.gov/ftp1/CTCAE)

24.

Rodríguez N, Sanz X, Dengra J, Foro P, Membrive I, Reig A, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87(5):1051–7.CrossRefPubMed

25.

Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no Boost” trial. Int J Radiat Oncol Biol Phys. 1999;45(3):667–76.CrossRefPubMed

26.

Vass S. Bairati i. A cosmetic evaluation of breast cancer treatment: a randomized study of radiotherapy boost technique. Int J Radiat Oncol Biol Phys. 2005;62(5):1274–82.CrossRefPubMed

27.

Brouwers P, Van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, Van Loon J, et al. On behalf of the Young Boost Trial research group Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial. Radiat. Oncol. 2016;120(1):107–13.CrossRef

28.

Purdie TG, Dinniwell RE, Letourneau D, Hill C, Sharpe MB. Automated planning of tangential breast intensity modulated radiotherapy using heuristic optimization. Int J Radiat Oncol Biol Phys. 2011;81(2):575–83.CrossRefPubMed

29.

Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial breast irradiation versus whole-breast irradiation for early-stage breast cancer: a decision-analysis. Int J Radiat Oncol Biol Phys. 2008;70(2):469–76.CrossRefPubMed

30.

Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, et al. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA. 2014;312(23):2542–50.CrossRefPubMedPubMedCentral

Titel: Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis
verfasst von: J. Sanz
N. Rodríguez
P. Foro
J. Dengra
A. Reig
P. Pérez
I. Membrive
A. Ortiz
M. Codinach
M. Algara
Publikationsdatum: 21.09.2016
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 4/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1548-3

Springer Medizin

Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis